Brokerages Set Solventum Co. (NYSE:SOLV) PT at $68.29

Shares of Solventum Co. (NYSE:SOLV) have been assigned an average rating of “Hold” from the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $68.29.

A number of research firms have recently issued reports on SOLV. BTIG Research began coverage on Solventum in a report on Thursday, September 5th. They issued a “neutral” rating for the company. Wolfe Research assumed coverage on Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating for the company. Mizuho began coverage on Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price target on the stock. Morgan Stanley upped their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Finally, Stifel Nicolaus started coverage on shares of Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective for the company.

Solventum Trading Down 2.5 %

SOLV stock opened at $66.89 on Monday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The firm has a 50-day moving average of $70.95 and a two-hundred day moving average of $63.41. Solventum has a 12 month low of $47.16 and a 12 month high of $96.05.

Hedge Funds Weigh In On Solventum

Several large investors have recently made changes to their positions in SOLV. Davis Selected Advisers purchased a new stake in Solventum in the second quarter valued at approximately $273,070,000. Nuance Investments LLC acquired a new stake in shares of Solventum in the second quarter valued at $115,829,000. Newport Trust Company LLC purchased a new stake in shares of Solventum in the 2nd quarter valued at $98,976,000. Baupost Group LLC MA acquired a new position in Solventum during the 2nd quarter worth about $96,242,000. Finally, Hotchkis & Wiley Capital Management LLC purchased a new position in Solventum during the 3rd quarter valued at about $125,488,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.